CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation
Frontiers in Pharmacology · 08.01.2024 · 14
DOI: 10.3389/fphar.2023.1334440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.01.2024. Verfasst von Nathan D Seligson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH, United States. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Introduction
Polymorphisms in genes responsible for the metabolism and transport of tacrolimus have been demonstrated to influence clinical outcomes for patients following allogeneic hematologic stem cell transplant (allo-HSCT). However, the clinical impact of germline polymorphisms specifically for oral formulations of tacrolimus is not fully described.
Methods
To investigate the clinical impact of genetic polymorphisms in CYP3A4 , CYP3A5 , and ABCB1 on oral tacrolimus pharmacokinetics and clinical outcomes, we prospectively enrolled 103 adult patients receiving oral tacrolimus for the prevention of graft-versus-host disease (GVHD) following allo-HSCT. Patients were followed in the inpatient and outpatient phase of care for the first 100 days of tacrolimus therapy. Patients were genotyped for CYP3A5 *3 (rs776746), CYP3A4 *1B (rs2740574), ABCB1 exon 12 (rs1128503), ABCB1 exon 21 (rs2032582), ABCB1 exon 26 (rs1045642).
Results
Expression of CYP3A5 *1 was highly correlated with tacrolimus pharmacokinetics in the inpatient phase of care ( p < 0.001) and throughout the entirety of the study period ( p < 0.001). Additionally, Expression of CYP3A5 *1 was associated with decreased risk of developing AKI as an inpatient ( p = 0.06). Variants in ABCB1 were not associated with tacrolimus pharmacokinetics in this study. We were unable to discern an independent effect of CYP3A4 *1B or *22 in this population.
Conclusion
Expression of CYP3A5 *1 is highly influential on the pharmacokinetics and clinical outcomes for patients receiving oral tacrolimus as GVHD prophylaxis following allo-HSCT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, OH, United States.
- Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
- Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.
- Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, United States.
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, United States.
- Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States.
Förderung
- NIGMS NIH HHS
Zitieren
APA
Seligson, N. D., Zhang, X., Zemanek, M. C., Johnson, J. A., VanGundy, Z., Wang, D., Phelps, M. A., Roddy, J., Hofmeister, C. C., Li, J., & Poi, M. J. (2024). CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1334440
Vancouver
Seligson ND, Zhang X, Zemanek MC, Johnson JA, VanGundy Z, Wang D, et al. CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation. Frontiers in Pharmacology. 2024;14. doi:10.3389/fphar.2023.1334440
BibTeX
@article{Seligson2024,
author = {Seligson, Nathan D and Zhang, Xunjie and Zemanek, Mark C and Johnson, Jasmine A and VanGundy, Zachary and Wang, Danxin and Phelps, Mitch A and Roddy, Julianna and Hofmeister, Craig C and Li, Junan and Poi, Ming J},
title = {CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {14},
doi = {10.3389/fphar.2023.1334440}
}
EUVIMED